Vedanta Biosciences to Present at Jefferies 2018 Global Healthcare Conference

Cambridge, Massachusetts, May 30, 2018 - Vedanta Biosciences, an affiliate of PureTech Health (LSE: PRTC) developing a new category of therapies for immune-mediated and infectious diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced that Chief Executive Officer, Bernat Olle, Ph.D., will present at the Jefferies 2018 Global Healthcare Conference in New York City on Friday, June 8, at 2:00PM EDT.

About Vedanta Biosciences

Vedanta Biosciences is pioneering development of a new category of therapies for immune-mediated and infectious diseases based on rationally-defined consortia of bacteria derived from the human microbiome. An affiliate of PureTech Health (PureTech Health plc, PRTC.L), Vedanta's founding team includes a group of world-renowned experts in immunology and microbiology. Vedanta Biosciences is a leader in the microbiome field with capabilities and deep expertise to discover, develop and manufacture drugs based on live bacterial consortia. The Company's facilities include integrated manufacturing operations providing cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form. Leveraging its proprietary technology platform and the expertise of its team of scientific co-founders, Vedanta Biosciences has isolated and maintains what we believe to be the largest collection of human microbiome-associated bacterial strains and has characterized, in collaborations with leading experts, how the immune system recognizes and responds to these microbes. This pioneering work has led to the identification of human commensal bacteria that induce a range of immune responses - including induction of regulatory T cells, CD8+ T cells, and Th17 cells, among others - as well as the characterization of novel molecular mechanisms of microbial-host communication. These advances have been published in leading peer-reviewed journals including Science (multiple), Nature (multiple), Cell and Nature Immunology. Vedanta Biosciences has harnessed these biological insights, its proprietary library of microbiome-derived bacterial strains, as well as data from clinical translational collaborations, to generate a pipeline of programs addressing infectious diseases, autoimmune diseases, inflammation and immune-oncology indications.

Vedanta Biosciences' scientific co-founders have pioneered the fields of innate immunity, Th17 and regulatory T cell biology, and include Dr. Ruslan Medzhitov (Professor of Immunobiology at Yale), Dr. Alexander Rudensky (tri-institutional Professor at the Memorial Sloan-Kettering Institute, the Rockefeller University and Cornell University), Dr. Dan Littman (Professor of Molecular Immunology at NYU), Dr. Brett Finlay (Professor at the University of British Columbia) and Dr. Kenya Honda (Professor, Keio University School of Medicine). Vedanta Biosciences is backed by Seventure, Invesco Asset Management, and Rock Springs Capital and has collaborations with leading institutions including Janssen Biotech, Inc., NYU Langone Health and its Perlmutter Cancer Center, Stanford University School of Medicine, Leiden University Medical Center, University of Tokyo, Keio University, RIKEN, and the University of South Alabama Mitchell Cancer Institute.

Contact:

Investors U.S. media
Allison Mead Talbot
+1 617 651 3156
amt@puretechhealth.com
Tom Donovan
+1 857 559 3397
tom@tenbridgecommunications.com